$9.59
0.36% yesterday
Nasdaq, Nov 25, 10:02 pm CET
ISIN
US03828A1016
Symbol
APLT
Sector
Industry

Applied Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Applied Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Applied Therapeutics, Inc. Price Target

Target Price $12.75
Price $9.59
Potential
Number of Estimates 4
4 Analysts have issued a price target Applied Therapeutics, Inc. 2025 . The average Applied Therapeutics, Inc. target price is $12.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 6 Analysts recommend Applied Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Applied Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Applied Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million $ 9.99 1.90
80.94%
EBITDA Margin -642.44% -4,303.52%
569.87%
Net Margin -1,653.97% -7,885.46%
376.76%

5 Analysts have issued a sales forecast Applied Therapeutics, Inc. 2024 . The average Applied Therapeutics, Inc. sales estimate is

$1.9m
Unlock
. This is
82.14% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.3m 59.74%
Unlock
, the lowest is
$500k 95.31%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $10.0m
2024
$1.9m 80.94%
Unlock
2025
$68.3m 3,487.16%
Unlock
2026
$167m 144.94%
Unlock
2027
$273m 63.10%
Unlock
2028
$385m 41.03%
Unlock

1 Analyst has issued an EBITDA forecast Applied Therapeutics, Inc. 2024 . The average Applied Therapeutics, Inc. EBITDA estimate is

$-81.9m
Unlock
. This is
32.04% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-81.9m 32.04%
Unlock
, the lowest is
$-81.9m 32.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-64.2m 22.22%
2024
$-81.9m 27.64%
Unlock
2025
$-41.9m 48.89%
Unlock
2026
$80.9m 293.19%
Unlock

EBITDA Margin

2023 -642.44%
2024
-4,303.52% 569.87%
Unlock
2025
-61.31% 98.58%
Unlock
2026
48.36% 178.88%
Unlock

1 Analyst has issued a net profit forecast Applied Therapeutics, Inc. 2024 . The average Applied Therapeutics, Inc. net profit estimate is

$-150m
Unlock
. This is
2.28% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-150m 2.28%
Unlock
, the lowest is
$-150m 2.28%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-165m 34.86%
2024
$-150m 9.16%
Unlock
2025
$-69.8m 53.48%
Unlock
2026
$-58.2m 16.67%
Unlock

Net Margin

2023 -1,653.97%
2024
-7,885.46% 376.76%
Unlock
2025
-102.24% 98.70%
Unlock
2026
-34.79% 65.97%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share $ -1.42 -1.29
34.86% 9.15%
P/E negative
EV/Sales 522.11

1 Analysts have issued a Applied Therapeutics, Inc. forecast for earnings per share. The average Applied Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.29
Unlock
. This is
2.27% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.29 2.27%
Unlock
, the lowest is
$-1.29 2.27%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.42 34.86%
2024
$-1.29 9.15%
Unlock
2025
$-0.60 53.49%
Unlock
2026
$-0.50 16.67%
Unlock

P/E ratio

Current -7.26 418.57%
2024
-7.43 2.34%
Unlock
2025
-15.98 115.07%
Unlock
2026
-19.18 20.03%
Unlock

Based on analysts' sales estimates for 2024, the Applied Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

522.11
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
586.19
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 93.23 832.30%
2024
522.11 460.03%
Unlock
2025
14.55 97.21%
Unlock
2026
5.94 59.17%
Unlock
2027
3.64 38.69%
Unlock
2028
2.58 29.09%
Unlock

P/S ratio

Current 104.68 681.03%
2024
586.19 460.00%
Unlock
2025
16.34 97.21%
Unlock
2026
6.67 59.17%
Unlock
2027
4.09 38.69%
Unlock
2028
2.90 29.09%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today